Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome (immunoprop)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2013 by New York CFS Association
Sponsor:
Information provided by (Responsible Party):
New York CFS Association
ClinicalTrials.gov Identifier:
NCT01893619
First received: July 2, 2013
Last updated: July 24, 2013
Last verified: July 2013
  Purpose

Observational study regarding the use of supplements in chronic fatigue syndrome patients


Condition
Chronic Fatigue Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome

Resource links provided by NLM:


Further study details as provided by New York CFS Association:

Primary Outcome Measures:
  • Karnovsky score comparison [ Time Frame: Six months ] [ Designated as safety issue: No ]
    Review of Karnofsky score over prior to diagnosis and subsequent to patients having taken supplements


Estimated Enrollment: 100
Study Start Date: June 2013
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Detailed Description:

Detailed questionnaire regarding the diagnosis of an onset of chronic fatigue syndrome and 100 patients. using Karnofsky scale before and after use of supplements patient scores are compared in a double blind trial.

  Eligibility

Ages Eligible for Study:   21 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Fukuda criteria and Canadian consensus criteria will be the diagnosis criteria for patient selection

Criteria

Inclusion Criteria:

  • Fukuda criteria and Canadian consensus criteria will be the diagnosis criteria for patient selection

Exclusion Criteria:

  • non inclusion in the above criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01893619

Locations
United States, New York
Me/Cfs Center,860 Fifth Avenue Recruiting
New York, New York, United States, 10065
Contact: derek enlander, MD    212-794-2000    denlander@aol.com   
Principal Investigator: derek enlander, md         
Sponsors and Collaborators
New York CFS Association
Investigators
Principal Investigator: DEREK enlander CFIDS RESEARCH FOUNDATION
  More Information

No publications provided

Responsible Party: New York CFS Association
ClinicalTrials.gov Identifier: NCT01893619     History of Changes
Other Study ID Numbers: immunoprop
Study First Received: July 2, 2013
Last Updated: July 24, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by New York CFS Association:
Chronic fatigue syndrome
Karnofsky score
supplements

Additional relevant MeSH terms:
Fatigue Syndrome, Chronic
Fatigue
Syndrome
Signs and Symptoms
Virus Diseases
Muscular Diseases
Musculoskeletal Diseases
Encephalomyelitis
Central Nervous System Diseases
Nervous System Diseases
Neuromuscular Diseases
Disease
Pathologic Processes

ClinicalTrials.gov processed this record on September 22, 2014